![Medicare Expands Coverage of Molecular Cancer Screening Tests](https://www.g2intelligence.com/wp-content/uploads/2023/05/May23.LIR_.MedicareGeneticTestCoverage-iStock-1169304873-1100x800-1-1080x675.jpg)
Medicare Expands Coverage of Molecular Cancer Screening Tests
In terms of Medicare coverage, 2023 is shaping up to be a fruitful year—here are five of the most significant approvals so far.
In terms of Medicare coverage, 2023 is shaping up to be a fruitful year—here are five of the most significant approvals so far.
In an analysis of enforcement actions from the end of 2022 to early spring 2023, cases involving urine drug testing were the most prevalent.
Though there are currently no clinical guidelines for their use, PRSs are being widely used in health care.
Recently released NGS systems will be helpful to researchers but are unlikely to immediately impact diagnostics, expert says.
The inexpensive POC device is a biosensor that performs COMT genotyping as a biomarker for hypnotizability.